# ClinicalTrials.gov record NCT02770391

> PeptideScanner retained ClinicalTrials.gov record NCT02770391 at 2026-07-30T19:38:43.103Z. Its registry update date was 2022-06-21, and PeptideScanner's reviewed identity mapping was leuprolide.

- Evidence object: `story:clinicaltrials-gov-nct02770391-leuprolide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-06-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02770391-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02770391-leuprolide-v1.json
- Content SHA-256: `f09fc860477b8b91cb62b9d732d653e3fa18b1f021edb6e890c580ba12aa9ea6`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT02770391 ([`ctg-observation-nct02770391-2022-06-21-ead131305a5f`](#source-ctg-observation-nct02770391-2022-06-21-ead131305a5f))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02770391 at 2026-07-30T19:38:43.103Z. Its registry update date was 2022-06-21, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02770391-2022-06-21-ead131305a5f`](#source-ctg-observation-nct02770391-2022-06-21-ead131305a5f))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02770391 at 2026-07-30T19:38:43.103Z. Its registry update date was 2022-06-21, and PeptideScanner's reviewed identity mapping was leuprolide. ([`ctg-observation-nct02770391-2022-06-21-ead131305a5f`](#source-ctg-observation-nct02770391-2022-06-21-ead131305a5f))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02770391-2022-06-21-ead131305a5f`](#source-ctg-observation-nct02770391-2022-06-21-ead131305a5f))

## Sources

<a id="source-ctg-observation-nct02770391-2022-06-21-ead131305a5f"></a>
- **ClinicalTrials.gov record NCT02770391 · retained source version 2022-06-21:ead131305a5f413ff45f190c4cc2b8465d0537a50e5af8ddd2ec6109af14cd72** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02770391) (`ctg-observation-nct02770391-2022-06-21-ead131305a5f`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02770391." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct02770391-leuprolide-v1.json SHA-256: f09fc860477b8b91cb62b9d732d653e3fa18b1f021edb6e890c580ba12aa9ea6.